uniQure (NASDAQ:QURE) Trading Up 5.2% Following Analyst Upgrade

uniQure (NASDAQ:QURE) shot up 5.2% during trading on Friday after The Goldman Sachs Group raised their price target on the stock from $9.00 to $20.00. The Goldman Sachs Group currently has a neutral rating on the stock. uniQure traded as high as $15.89 and last traded at $15.85. 460,962 shares traded hands during trading, a decline of 72% from the average session volume of 1,640,178 shares. The stock had previously closed at $15.06.

Several other equities research analysts have also commented on QURE. Leerink Partners upped their price objective on uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research note on Wednesday. Royal Bank of Canada upped their price target on uniQure from $14.00 to $20.00 and gave the stock an “outperform” rating in a research report on Wednesday. StockNews.com raised uniQure to a “sell” rating in a research report on Wednesday. Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the company from $20.00 to $52.00 in a research note on Tuesday, December 10th. Finally, Wells Fargo & Company raised shares of uniQure from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, five have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, uniQure presently has an average rating of “Moderate Buy” and a consensus target price of $32.14.

Insider Activity

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the transaction, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. This represents a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.74% of the company’s stock.

Institutional Investors Weigh In On uniQure

Several large investors have recently bought and sold shares of QURE. abrdn plc grew its stake in shares of uniQure by 381.7% in the 3rd quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after buying an additional 1,528,581 shares in the last quarter. Franklin Resources Inc. bought a new stake in uniQure during the third quarter worth approximately $7,360,000. Point72 Asset Management L.P. increased its stake in uniQure by 336.1% during the third quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock worth $4,816,000 after acquiring an additional 752,889 shares during the last quarter. FMR LLC raised its holdings in uniQure by 8,056.6% during the 3rd quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock valued at $1,728,000 after buying an additional 346,274 shares during the period. Finally, Assenagon Asset Management S.A. bought a new stake in uniQure in the second quarter worth $815,000. Institutional investors own 78.83% of the company’s stock.

uniQure Price Performance

The company has a market capitalization of $750.60 million, a PE ratio of -3.10 and a beta of 0.89. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The firm’s 50 day simple moving average is $7.04 and its 200 day simple moving average is $6.36.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The firm had revenue of $2.29 million during the quarter, compared to analyst estimates of $2.73 million. As a group, research analysts anticipate that uniQure will post -3.81 EPS for the current fiscal year.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.